Bionano Genomics (BNGO) Cash & Equivalents (2017 - 2026)

Bionano Genomics has reported Cash & Equivalents for 10 years, with the latest figure at $3.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 5.52% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 5.52% YoY) and the FY2025 annual result came in at $3.0 million, down 67.4% from the prior year.
• Cash & Equivalents grew to $3.4 million in Q1 2026 per BNGO's latest filing, from $3.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $34.6 million in Q3 2023 and troughed at $3.0 million in Q4 2025.
• A 5-year average of $12.8 million and a median of $9.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 93.36% in 2022, then surged 283.99% in 2024.
• Over 5 years, Cash & Equivalents stood at $5.1 million in 2022, then soared by 252.54% to $17.9 million in 2023, then sank by 48.89% to $9.2 million in 2024, then slumped by 67.4% to $3.0 million in 2025, then advanced by 14.55% to $3.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.4 million, $3.0 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.